Abstract
Liraglutide, an analog of glucagon-like peptide-1 (GLP-1), is an effective anti-diabetic agent with few side effects. Since native GLP-1 exerts vascular effects, we investigated changes in pancreatic islet blood flow using a non-radioactive microsphere technique, as well as insulin concentration and glucose tolerance after 17 day treatment with liraglutide in 6-week-old Goto-Kakizaki (GK) rats. Compared to saline-treated control GK rats, liraglutide limited body weight gain, decreased glycemia, improved glucose tolerance and lowered serum insulin concentration. Neither pancreatic or islet blood flow, nor pancreatic insulin content, was affected by liraglutide treatment. We conclude that early intervention with liraglutide decreases glycemia and improves glucose tolerance, thus halting the natural progression towards diabetes, without affecting islet microcirculation or pancreatic insulin content in young female GK rats.
References
Dec 1, 1994·Diabetes/metabolism Reviews·L Jansson
Jun 1, 1994·European Journal of Endocrinology·A M SvenssonC G Ostenson
Oct 15, 1998·Autoimmunity·U B ChristensenJ Nerup
May 5, 2000·Journal of Medicinal Chemistry·L B KnudsenH Agersø
Feb 22, 2001·European Journal of Endocrinology·M IwaseL Jansson
Jul 30, 2002·Diabetes·Masanori IwaseMitsuo Iida
Sep 12, 2003·British Journal of Pharmacology·Jeppe SturisLotte Bjerre Knudsen
Feb 5, 2004·Regulatory Peptides·Lene HansenJens J Holst
Feb 26, 2004·Circulation·Lazaros A NikolaidisRichard P Shannon
Sep 9, 2004·American Journal of Physiology. Endocrinology and Metabolism·Thomas NyströmAke Sjöholm
Dec 8, 2004·Regulatory Peptides·Thomas NyströmJohn Pernow
Dec 24, 2004·Diabetes·Amal K BoseDerek M Yellon
Mar 31, 2005·Biochemical and Biophysical Research Communications·Søren BregenholtJacob S Petersen
Apr 5, 2005·Endocrine·Rengasamy PalanivelAnjaneyulu Kowluru
Jun 8, 2006·Biochemical and Biophysical Research Communications·Zhen HuangAke Sjöholm
Oct 6, 2006·Clinical Science·Zhen HuangAke Sjöholm
Nov 3, 2006·Pancreas·Sophie CalderariPatricia Serradas
Nov 8, 2006·Clinical Science·Annika M SvenssonLeif Jansson
Nov 14, 2006·Lancet·Daniel J Drucker, Michael A Nauck
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
Jul 20, 2007·Obesity·Kirsten RaunLotte Bjerre Knudsen
Oct 6, 2007·Endocrinology·Zhen Huang, Ake Sjöholm
Nov 8, 2007·American Journal of Physiology. Endocrinology and Metabolism·Jamileh MovassatBernard Portha
Dec 26, 2007·Clinical Therapeutics·Anthony H BarnettMichael E Trautmann
Jan 22, 2008·Clinical Science·Zhen HuangAke Sjöholm
Jul 22, 2008·Molecular and Cellular Endocrinology·B PorthaJ Movassat
Sep 30, 2008·Lancet·Alan GarberUNKNOWN LEAD-3 (Mono) Study Group
Mar 22, 2010·Pharmaceuticals·Åke Sjöholm
Citations
Jan 16, 2014·Diabetology & Metabolic Syndrome·Liselotte FranssonHenrik Ortsäter
Dec 19, 2013·PloS One·Balaji SamikannuThomas Linn
Apr 18, 2013·Journal of Diabetes·Xiu LuoXiaoying Li
May 30, 2013·Clinical Science·Anna OlverlingÅke Sjöholm
Apr 22, 2016·Drug Delivery·Lixue ZhangLi Yang
Sep 18, 2017·Journal of Endocrinological Investigation·X XuX Gao
Dec 21, 2018·Journal of Applied Physiology·Jefferson C FrisbeeRobert W Wiseman
Mar 8, 2017·Microcirculation : the Official Journal of the Microcirculatory Society, Inc·Nikolaj NerupLars B Svendsen
Apr 20, 2018·Physiological Reports·Xiang GaoLeif Jansson
May 7, 2016·Nanoscale·F AraújoB Sarmento